Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

(MedPage Today) — HOUSTON — Survival in untreated, intermediate- and higher-risk myelodysplastic syndromes (MDS) failed to improve with the addition of the targeted agent venetoclax (Venclexta) to chemotherapy, a large randomized trial showed…

Source link : https://www.medpagetoday.com/meetingcoverage/soho/117342

Author :

Publish date : 2025-09-06 17:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

Are You Ready for Measles’ Wrath?

Who Needs a Beta-Blocker After a Heart Attack? RSV Vaccines and Hospitalizations

Related Posts

Here’s What RFK Jr., FDA Got Wrong About Menopausal Hormone Therapy

Inside the UK’s Battle Against Counterfeit Drugs

Pediatrician Killed in Crash; Neurosurgeon’s Gun Arrest; Army Ob/Gyn Lawsuit

Noninvasive Imaging Test Provides Answers in Angina With No Obstructive Arteries

A simple hack to help you switch off after work

Ultraprocessed Foods Tied to Early Colorectal Adenoma Risk

Here’s What RFK Jr., FDA Got Wrong About Menopausal Hormone Therapy

Inside the UK’s Battle Against Counterfeit Drugs

Pediatrician Killed in Crash; Neurosurgeon’s Gun Arrest; Army Ob/Gyn Lawsuit

Noninvasive Imaging Test Provides Answers in Angina With No Obstructive Arteries

A simple hack to help you switch off after work

Ultraprocessed Foods Tied to Early Colorectal Adenoma Risk

Livers of MASLD Patients End Up Less Fatty With Novel Injectable

U.S. Bishops Officially Ban Gender-Affirming Care at Catholic Hospitals

Categories

Archives